Table 3.
The frequency of BRM polymorphisms in smokers and nonsmokers with upper aerodigestive tract cancers.
| Adjusted OR (95% CI)1 cases vs. controls |
|||
|---|---|---|---|
| BRM polymorphism | Ever-smokers | Nonsmokers | Interaction P-value |
| All cancers | |||
| Wild type (reference) | 1 | 1 | 0.32 |
| Heterozygote (for either variant) | 1.36 (0.8–2.2) | 1.39 (0.7–2.6) | |
| BRM-741 homozygote only | 1.26 (0.6–3.2) | 1.43 (0.9–3.9) | |
| BRM-1321 homozygote only | 1.25 (0.6–3.2) | 1.35 (0.5–4.0) | |
| BRM-741 and-1321 homozygotes | 2.38 (1.3–4.4) | 2.62 (1.2–5.0) | |
| Lung cancer | |||
| Wild type (reference) | 1 | 1 | 0.55 |
| Heterozygote (for either variant) | 1.33 (0.5–3.7) | 1.36 (0.6–4.7) | |
| BRM-741 homozygote only | 1.38 (0.5–4.5) | 1.42 (0.4–5.0) | |
| BRM-1321 homozygote only | 1.66 (0.9–4.7) | 1.25 (0.4–5.2) | |
| BRM-741 and-1321 homozygotes | 2.40 (1.2–4.4) | 2.49 (1.0–5.0) | |
| Esophageal cancer | |||
| Wild type (reference) | 1 | 1 | 0.88 |
| Heterozygote (for either variant) | 1.05 (0.4–3.6) | 1.09 (0.3–4.1) | |
| BRM-741 homozygote only | 1.15 (0.4–4.2) | 1.13 (0.3–4.8) | |
| BRM-1321 homozygote only | 1.22 (0.3–3.9) | 1.00 (0.3–5.1) | |
| BRM-741 and-1321 homozygotes | 1.81 (0.6–3.0) | 1.52 (0.6–4.3) | |
| Head and neck cancer | |||
| Wild type (reference) | 1 | 1 | 0.42 |
| Heterozygote (for either variant) | 1.41 (0.7–4.2) | 1.55 (0.8–5.2) | |
| BRM-741 homozygote only | 1.51 (0.6–4.8) | 1.58 (0.5–6.0) | |
| BRM-1321 homozygote only | 1.56 (0.8–5.6) | 1.47 (0.6–6.3) | |
| BRM-741 and-1321 homozygotes | 2.53 (1.4–4.5) | 3.15 (1.4–6.4) | |
BRM, Brahma; OR, odds ratio; CI, confidence interval; UADT, upper aerodigestive tract.
1
The OR was adjusted for: age, sex, smoking status, pack-years, and family history of UADT cancers.